Vikas Gupta
YOU?
Author Swipe
View article: Is There a Measurable Placebo Effect in Policy Announcements?
Is There a Measurable Placebo Effect in Policy Announcements? Open
This paper tests whether policy announcements generate a distinct "placebo" effect: an incremental same-day reaction beyond what is explained by the news sign (positive or negative) and the time remaining to implementation. We assemble a m…
View article: Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis
Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis Open
View article: Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis
Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis Open
Patients with myelofibrosis (MF) who are resistant to or relapse after Janus kinase inhibitor (JAKi) therapy have limited treatment options and typically poor prognoses. CD123 is overexpressed in various myeloid malignancies, including MF.…
View article: PATTERN OF ANTIBIOTIC RESISTANCE OF BACTERIAL PATHOGENS IN PATIENTS ADMITTED IN MEDICINE ICU OF TERTIARY CARE CENTRE
PATTERN OF ANTIBIOTIC RESISTANCE OF BACTERIAL PATHOGENS IN PATIENTS ADMITTED IN MEDICINE ICU OF TERTIARY CARE CENTRE Open
View article: Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study
Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study Open
View article: ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis Open
Ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, is the standard of care for symptomatic patients with myelofibrosis (MF). However, ∼70% of patients discontinue ruxolitinib after ∼5 years, a third of whom report suboptimal splenic respon…
View article: Spinal anaesthesia to caesarean section: Patient satisfaction
Spinal anaesthesia to caesarean section: Patient satisfaction Open
Patient satisfaction on spinal anaesthesia to caesarean section is of interest. Hence, data from 60 female doctors of various disciplines working in Bhopal city who underwent caesarean section under spinal anaesthesia during the last 5 yea…
View article: Limits on the Ejecta Mass During the Search for Kilonovae Associated with Neutron Star-Black Hole Mergers: A case study of S230518h, GW230529, S230627c and the Low-Significance Candidate S240422ed
Limits on the Ejecta Mass During the Search for Kilonovae Associated with Neutron Star-Black Hole Mergers: A case study of S230518h, GW230529, S230627c and the Low-Significance Candidate S240422ed Open
Neutron star-black hole (NSBH) mergers, detectable via their gravitational-wave (GW) emission, are expected to produce kilonovae (KNe). Four NSBH candidates have been identified and followed-up by more than fifty instruments since the star…
View article: Artificial Intelligence in Orthodontics: Evaluating Diagnostic Accuracy and Treatment Planning Efficiency
Artificial Intelligence in Orthodontics: Evaluating Diagnostic Accuracy and Treatment Planning Efficiency Open
Background: The integration of artificial intelligence (AI) in orthodontics promises to enhance diagnostic accuracy and optimize treatment planning. However, its clinical efficacy and reliability remain areas of active investigation. This …
View article: Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial Open
View article: Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms
Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms Open
View article: L’incidence du rôle d’infirmière clinicienne spécialisée dans le programme des néoplasies myéloprolifératives : Deuxième partie – L’expérience des soins des patients et de l’équipe
L’incidence du rôle d’infirmière clinicienne spécialisée dans le programme des néoplasies myéloprolifératives : Deuxième partie – L’expérience des soins des patients et de l’équipe Open
Les néoplasies myéloprolifératives forment un groupe de troubles clonaux rares des cellules progénitrices hématopoïétiques; elles sont associées à des symptômes propres à la maladie, à des événements thrombotiques et à un risque d’évolutio…
View article: L’influence du rôle d’infirmière clinicienne spécialisée dans le programme des néoplasies myéloprolifératives : Première partie – De la rapidité du triage aux économies de coûts
L’influence du rôle d’infirmière clinicienne spécialisée dans le programme des néoplasies myéloprolifératives : Première partie – De la rapidité du triage aux économies de coûts Open
Les néoplasies myéloprolifératives forment un groupe de troubles clonaux rares des cellules progénitrices hématopoïétiques; elles sont associées à des symptômes propres à la maladie, à des événements thrombotiques et à un risque d’évolutio…
View article: Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part One – From timeliness of triage to cost-saving
Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part One – From timeliness of triage to cost-saving Open
Myeloproliferative neoplasms (MPNs) are a group of rare clonal disorders of hematopoietic progenitor cells associated with disease-related symptoms, thrombotic events, and risk of transformation to acute myeloid leukemia (Tefferi, 2021). T…
View article: Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy Open
View article: Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study
Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study Open
Myelofibrosis (MF), a myeloproliferative neoplasm, was most commonly treated with hydroxyurea (HU) before approval of ruxolitinib (RUX), now the standard of care. Factors that influence real-world MF treatment patterns are not well underst…
View article: A Perspective Studies: Nutritional Interventions and their Impact on Geriatric Health Outcomes
A Perspective Studies: Nutritional Interventions and their Impact on Geriatric Health Outcomes Open
View article: Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML
Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML Open
View article: Exhaled Breath Condensate Surveillance for <i>Aspergillus</i> in Acute Leukemia—a Pilot Trial
Exhaled Breath Condensate Surveillance for <i>Aspergillus</i> in Acute Leukemia—a Pilot Trial Open
Invasive fungal infections in patients with leukemia carry a high mortality rate, but early diagnosis has the potential to modify this natural history. A novel screening method using Aspergillus droplet-digital polymerase chain reaction in…
View article: Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis Open
With emerging new drugs in myelofibrosis (MF), a robust and harmonized framework for defining the severity of anemia and response to treatment will enhance clinical investigation and facilitate interstudy comparisons. Accordingly, the lead…
View article: Unmasking Job Satisfaction: Insights from Tribal India’s Nurses amongst the COVID-19 Pandemic
Unmasking Job Satisfaction: Insights from Tribal India’s Nurses amongst the COVID-19 Pandemic Open
Background: Even prior to the pandemic, India’s nursing workforce faced a severe shortage, exacerbating the challenges they now face during the global health crisis. When compared to the WHO norm of 1:300, the lack of trained nurses is muc…
View article: Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group
Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group Open
View article: Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib
Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib Open
Pacritinib demonstrates consistent efficacy in patients with MF regardless of baseline platelet and hemoglobin counts.
View article: Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study Open
We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation (HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant Research registry data for HCTs done between 2013 and 2019. In a…
View article: Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial Open
The phase 3b FREEDOM trial (ClinicalTrials.gov: NCT03755518) evaluates efficacy/safety of fedratinib in intermediate- or high-risk myelofibrosis patients with platelet count ≥50 × 109/L, previously treated with ruxolitinib. The …
View article: Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era Open
Progression of myeloproliferative neoplasms (MPNs) to accelerated or blast phase is associated with poor survival outcomes. Since 2017 there have been several therapies approved for use in acute myeloid leukemia (AML); these therapies have…
View article: Immunogenicity of Covishield vaccine in patients with autoimmune rheumatic diseases
Immunogenicity of Covishield vaccine in patients with autoimmune rheumatic diseases Open
A BSTRACT Introduction: The Coronavirus disease 2019 (COVID-19) pandemic has been the biggest threat to humankind during the last 3 years. It has caused the loss of more than 6.9 million precious lives across the world. The only method by …
View article: Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase
Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase Open
This retrospective report presents the outcomes and adverse events (AEs) observed in 73 patients aged 60 years or older diagnosed with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (Ph-negative ALL) treated with a pediatric…
View article: Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial Open
A key hallmark of myelofibrosis is anemia, which ranges from mild to severe based on hemoglobin levels. To more clearly define outcomes with the Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor momelotinib by anemia severity, …
View article: Abstract No. 275 Long-Term Impact of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation on Hepatic Morphology
Abstract No. 275 Long-Term Impact of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation on Hepatic Morphology Open